Expression of myeloid and other antigens and cytochemistry of EBCs
| Disease . | CD11b . | CD13 . | CD14 . | CD15 . | CD33 . | CD34 . | HLA-DR . | CD38 . | CD117 . | GPA . | MPO3-150 . | EST3-150 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RA | 12/18 (30, 21-59) | 18/18 (78, 36-97) | 0/18 | 17/18 (44, 26-82) | 19/19 (70, 22-100) | 18/19 (79, 29-95) | 19/19 (95, 68-99) | 18/18 (96, 71-100) | 6/18 (44, 22-85) | 0/14 | 5/15 | 0/11 |
| RARS | 3/4 (34, 31-37) | 4/4 (69, 54-83) | 0/4 | 4/4 (44, 24-58) | 4/4 (61, 40-93) | 4/4 (58, 45-78) | 4/4 (85, 73-95) | 4/4 (91, 74-95) | 2/4 (25, 24-25) | 0/3 | 2/3 | 0/1 |
| CMML | 2/5 (44, 40-48) | 5/5 (96, 90-98) | 0/5 | 2/5 (64, 52-76) | 5/5 (64, 48-96) | 5/5 (92, 64-98) | 5/5 (84, 61-99) | 5/5 (96, 76-99) | 5/5 (85, 38-96) | 0/3 | 4/5 | 1/3 |
| RAEB | 15/35 (29, 22-60) | 36/36 (90, 44-100) | 0/36 | 21/36 (40, 23-73) | 36/36 (89, 25-100) | 34/36 (90, 35-99) | 36/36 (98, 39-100) | 35/35 (92, 36-100) | 28/36 (53, 25-85) | 0/22 | 13/36 | 2/22 |
| RAEB-t | 12/28 (37, 20-64) | 30/30 (93, 38-100) | 0/30 | 17/30 (41, 21-80) | 31/31 (86, 26-99) | 30/31 (95, 48-99) | 31/31 (96, 61-100) | 27/28 (91, 51-100) | 18/30 (65, 23-83) | 0/16 | 11/29 | 2/17 |
| AL-MDS | 9/21 (50, 23-95) | 21/21 (96, 77-99) | 0/21 | 12/21 (40, 24-99) | 19/21 (90, 24-100) | 21/21 (93, 26-100) | 21/21 (98, 24-100) | 19/21 (95, 61-100) | 14/21 (64, 21-92) | 1/21 (45) | 10/20 | 0/20 |
| Disease . | CD11b . | CD13 . | CD14 . | CD15 . | CD33 . | CD34 . | HLA-DR . | CD38 . | CD117 . | GPA . | MPO3-150 . | EST3-150 . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RA | 12/18 (30, 21-59) | 18/18 (78, 36-97) | 0/18 | 17/18 (44, 26-82) | 19/19 (70, 22-100) | 18/19 (79, 29-95) | 19/19 (95, 68-99) | 18/18 (96, 71-100) | 6/18 (44, 22-85) | 0/14 | 5/15 | 0/11 |
| RARS | 3/4 (34, 31-37) | 4/4 (69, 54-83) | 0/4 | 4/4 (44, 24-58) | 4/4 (61, 40-93) | 4/4 (58, 45-78) | 4/4 (85, 73-95) | 4/4 (91, 74-95) | 2/4 (25, 24-25) | 0/3 | 2/3 | 0/1 |
| CMML | 2/5 (44, 40-48) | 5/5 (96, 90-98) | 0/5 | 2/5 (64, 52-76) | 5/5 (64, 48-96) | 5/5 (92, 64-98) | 5/5 (84, 61-99) | 5/5 (96, 76-99) | 5/5 (85, 38-96) | 0/3 | 4/5 | 1/3 |
| RAEB | 15/35 (29, 22-60) | 36/36 (90, 44-100) | 0/36 | 21/36 (40, 23-73) | 36/36 (89, 25-100) | 34/36 (90, 35-99) | 36/36 (98, 39-100) | 35/35 (92, 36-100) | 28/36 (53, 25-85) | 0/22 | 13/36 | 2/22 |
| RAEB-t | 12/28 (37, 20-64) | 30/30 (93, 38-100) | 0/30 | 17/30 (41, 21-80) | 31/31 (86, 26-99) | 30/31 (95, 48-99) | 31/31 (96, 61-100) | 27/28 (91, 51-100) | 18/30 (65, 23-83) | 0/16 | 11/29 | 2/17 |
| AL-MDS | 9/21 (50, 23-95) | 21/21 (96, 77-99) | 0/21 | 12/21 (40, 24-99) | 19/21 (90, 24-100) | 21/21 (93, 26-100) | 21/21 (98, 24-100) | 19/21 (95, 61-100) | 14/21 (64, 21-92) | 1/21 (45) | 10/20 | 0/20 |
Data in the upper row for each disease subtype are the number of cases: positive cases/total cases analyzed. Data in parentheses are the percentages of blasts expressing each antigen in the positive cases (median, range).
Myeloperoxidase (MPO) and nonspecific esterase (EST) activities, determined by cytochemistry.